Nuevolution in Drug Discovery Alliance with Lexicon Pharmaceuticals
Nuevolution A/S has entered a strategic alliance with Lexicon Pharmaceuticals, Inc. aimed at the discovery of novel small molecule lead compounds for highly validated drug targets.
Under the terms of the alliance, Nuevolution’s proprietary Chemetics drug discovery technology will be applied to identify novel small molecule lead compounds against a range of drug targets proposed by Lexicon. The Chemetics platform technology enables both hit identification and hit-to-lead optimization by exploration of ultra large chemistry space through the screening of multiple fragment-based small molecule libraries of more than 100 million compounds per library.